Abstract Western populations are living longer. Ageing decline in muscle mass and strength (i.e. sarcopenia) is becoming a growing public health problem, as it contributes to the decreased capacity for independent living. It is thus important to determine those genetic factors that interact with ageing and thus modulate functional capacity and skeletal muscle phenotypes in older people. It would be also clinically relevant to identify 'unfavourable' genotypes associated with accelerated sarcopenia. In this review, we summarized published information on the potential associations between some genetic polymorphisms and muscle phenotypes in older people. A special emphasis was placed on those candidate polymorphisms that have been more extensively studied, i.e. angiotensinconverting enzyme (ACE) gene I/D, α-actinin-3 (ACTN3) R577X, and myostatin (MSTN) K153R, among others. Although previous heritability studies have indicated that there is an important genetic contribution to individual variability in muscle phenotypes among old people, published data on specific gene variants are controversial. The ACTN3 R577X polymorphism could influence muscle function in old women, yet there is controversy with regards to which allele (R or X) might play a 'favourable' role. Though more research is needed, up-to-date MSTN genotype is possibly the strongest candidate to explain variance among muscle phenotypes in the elderly. Future studies should take into account the association between muscle phenotypes in this population and complex gene-gene and gene-environment interactions.
Introduction
Due to Western societies populations living longer, there is a demand to understand the ageing process and to explore the mechanisms associated with healthy ageing and preservation of functional independence at the end of life. In elderly people, functional capacity is directly dependent on muscular fitness as these persons experience age-associated declines in skeletal muscle mass and function, i.e. sarcopenia (Rosenberg 1997) . Sarcopenia contributes to the decreased capacity for independent living associated with advanced age (Rexach et al. 2009 ) and imposes a significant economic burden. For instance, the estimated direct healthcare cost attributable to sarcopenia in the USA in 2000 was $18.5 billion, which represented about 1.5% of total healthcare expenditures for that year . It is thus important to understand how ageing and the interaction of ageing with lifestyle and genetic factors affect functional capacity and skeletal muscle phenotypes.
The influence of external factors, notably physical activity habits, on muscle phenotypes in the elderly has been investigated in depth (Daly et al. 2008; Liu and Latham 2011) , yet the heritability of muscle strength is less well-known. There is, however, evidence supporting that the extreme plasticity of human skeletal muscle in response to several stimuli (particularly, exercise) is genetically regulated (Stewart and Rittweger 2006) ; thus, several genetic variations may explain, at least partly, individual variations in muscle strength and muscular fitness in the elderly, such as unfavourable genotypes potentially associated with accelerated sarcopenia.
In this review, we compiled available information, based on genetic association studies, on those polymorphisms that are candidates to be associated with muscle phenotypes in the elderly. Our literature search was primarily based on the journals available in MEDLINE, the National Library of Medicine's publication database covering the fields of life sciences, biomedicine, and health using a combination of key words (genetics, genotype, polymorphism, muscle mass, strength, muscular fitness, training, exercise, physical activity, physical or functional performance, older, elderly). Articles published since April 2011 are not included in this review. The literature search was limited to articles published in English.
Sarcopenia in the elderly: a common problem
The European Working Group on Sarcopenia in Older People recently recommended using the presence of both low muscle mass (criterion 1) and low muscle function (i.e. strength (criterion 2) or performance (criterion 3)) for the diagnosis of sarcopenia (Cruz-Jentoft et al. 2010) . Thus, diagnosis requires documentation of criterion 1 plus documentation of either criterion 2 or criterion 3. As for cutoff values of muscle mass and function, Fielding et al. established that a diagnosis of sarcopenia is consistent with an objectively measured low muscle mass (e.g. appendicular mass relative to height 2 that is ≤7.23 kg m −2 in men and ≤5.67 kg m −2
in women) and a gait speed of less than 1 m s −1 (Fielding et al. 2011) . On a myocellular level, sarcopenia is characterized by a reduction in muscle fibre number as well as fibre size, with specific type II muscle fibre atrophy (Lexell et al. 1983 (Lexell et al. , 1988 . Muscle mass usually reaches its peak at the age of 25-30 years and thereafter begins to decline (Lexell et al. 1988; Janssen et al. 2000) . The decrease in muscle mass accelerates at the end of the fifth decade, when approximately 10% of the total muscle mass is usually lost; thus, at the age of 80 years, 40% of the muscle mass has disappeared on average (Lexell et al. 1988; Saini et al. 2009 ). The age-associated loss of muscle strength is more rapid than the parallel loss of muscle mass, suggesting a decline in muscle quality with ageing (Goodpaster et al. 2006) . In sedentary people, muscle strength decreases by 1-3% per year after the third decade of life, and this rate of decrease can be higher after the eight decade (Connelly and Vandervoort 1997) . Sarcopenia contributes to the onset and progression of disability with advancing age (Hairi et al. 2010) . Sarcopenia can induce muscle weakness and reduced ability to produce rapid force, which are considered to be two of the most common risk factors associated with falls and loss of functional independence in older adults (Taaffe and Marcus 2000; Buchman et al. 2007) . Sarcopenia can be explained by several physiopathological factors including (a) progressive muscle denervation (Deschenes 2004; Saini et al. 2009 ); (b) alterations in muscle protein turnover, specifically manifested by difficulty to increase protein synthesis (Kumar et al. 2009 ); (c) malnutrition (Doherty 2003) ; (d) altered expression levels of anabolic hormones (Volpi et al. 2004) ; (e) increased levels of pro-inflammatory cytokines (Kamel 2003) ; (f) increased oxidative stress (Howard et al. 2007 ); (g) lower physical activity levels (Cesari and Pahor 2008) and (h) diminished number and function of satellite cells in skeletal muscles (Verdijk et al. 2007) . Concerning the latter, satellite cells are the main contributor to muscle maintenance, growth and repair (Anderson and Wozniak 2004) . Thus, a decline in the number of satellite cells (Kadi et al. 2004; Renault et al. 2002; Verdijk et al. 2007) or their inability to become active and proliferate in response to anabolic stimuli (Conboy et al. 2003; Conboy and Rando 2002 ) may contribute to the development of sarcopenia.
The prevalence of sarcopenia varies among studies depending on the race, age and sex of the studied samples, or the assessment tool (Abellan van Kan 2009). For instance, a recent report showed a prevalence of 42% in a cohort of 250 North American women aged 76-86 years (Frisoli et al. 2011) . The lack of a standardized definition of sarcopenia until recently, at least in terms of cutoff points of muscle mass and function (Cruz-Jentoft et al. 2010; Fielding et al. 2011) , has been an important recognized impediment to epidemiologic studies in the field.
Heritability studies
Heritability describes the extent to which differences in a phenotype are explained by genetic differences in a certain population at a certain time (Plomin et al. 2001) . Heritability studies in humans have found overall genetic contributions of up to 66% for muscle mass (Abney et al. 2001 ) and 65% for muscle strength (Reed et al. 1991) . The heritability of a given phenotype can be analysed in twin studies. Published research with older twins has reported that heritability can explain 22% to 52% of the variance in muscle strength, the latter been typically assessed with handgrip dynamometry (Arden and Spector 1997; Carmelli and Reed 2000; Frederiksen et al. 2002; Reed et al. 1991) . The relative contribution of genetic and environmental effects to the individual variability in muscle strength changes over the ageing process. During a 10-year follow-up in male twins with a mean age of 63 years at baseline, the heritability of handgrip strength decreased from 35% to 22%, while the shared environmental effects increased from 39% to 45% (Carmelli and Reed 2000) . Age-related diseases can also influence the heritability of muscle strength in the elderly. In a study of 1,757 Danish twins aged 45-96 years, Frederiksen et al. found that excluding individuals with chronic diseases (cardiopulmonary diseases, diabetes, stroke, cancer excluding skin cancer, osteoarthritis or osteoporosis) increased the heritability estimate from 52% to 62%, owing to a reduction in environmental variability (Frederiksen et al. 2002) . Some data are also available on the heritability of muscle phenotypes in the lower extremities of old people. In research conducted on monozygotic and dizygotic female Finnish twin pairs aged 63-76 years, Tiainen and colleagues found that genetic effects accounted for 20-30% of the variance in handgrip strength, leg extensor power and maximal walking speed (Tiainen et al. 2004 (Tiainen et al. , 2005 (Tiainen et al. , 2008 (Tiainen et al. , 2009 .
Muscle cross-sectional area (CSA) and lean body mass (LBM), which are close approximates of total body muscle mass, seem to be under a relatively strong genetic regulation across the human lifespan. Among boys and girls aged 10-14 years, genetic effects accounted for 87-95% of the variation in the circumference of the muscles of the upper and lower extremities (Loos et al. 1997) . A heritability of more than 85% was observed for arm CSA among male twins aged 17-30 years (Thomis et al. , 1998 . Genetic effects accounted for 52-84% of the variation in LBM among older female twins, i.e. women averaging 45 years (Seeman et al. 1996) or~53 years of age (Nguyen et al. 1998 ) and premenopausal women (Arden and Spector 1997) . In a study by Schousboe et al., the heritability of LBM was 61% among female twins aged 18-67 years (Schousboe et al. 2004 ). Forbes et al. reported a heritability of 70% for LBM in twin pairs of the same sex over the age range of 7-85 years (Forbes et al. 1995) .
On the other hand, the findings of several multivariate genetic studies suggest a shared pleiotropic gene action for the different muscle phenotypic characteristics (Thomis et al. , 1998 Tiainen et al. 2004 Tiainen et al. , 2005 De Mars et al. 2007 ). This would imply that different muscle phenotypes share the same chromosomal region with suggestive or significant evidence for linkage (De Mars et al. 2008 ).
Genotype-phenotype association studies
A large number of candidate genes have been studied to identify potential statistical associations with muscle-related phenotypes in a wide range of population groups of varying ages (Bray et al. 2009 ). Some of the studied genetic variations could be also associated with muscle phenotypes in the elderly. We included in our review all the genetic association studies in which the mean or minimum age range of the cohort (or at least of one study cohort in those reports with ≥2 cohorts) was ≥60 years. We also included some studies with large cohorts with a mean age (or minimum age range) <60 years, but in which subanalyses were performed in a subset of participants aged ≥60 years (Schrager et al. 2004; Roth et al. 2001) . We also included in our review two studies by Walsh et al. with large cohorts of a wide age range because the mean age of each study cohort was ≥60 years, as deduced from the information provided in the tables of these two papers (Walsh et al. , 2008 .
Summary of the functional significant polymorphisms studied in previous genotype-phenotype association reports A n g i o t e n s i n -c o n v e r t i n g e n z y m e g e n e I / D polymorphism The I/D polymorphism (rs1799752) of the human angiotensin-converting enzyme (ACE) gene is defined by the presence (insertion, I allele) or absence (deletion, D allele) of a 287-bp fragment in intron 16 (Rigat et al. 1990 ). The D and I alleles are usually associated with higher and lower ACE enzyme activity respectively (Danser et al. 1995; Tiret et al. 1992; Williams et al. 2005) . The primary role of ACE in the renin-angiotensin system is to convert angiotensin I into angiotensin II (Rigat et al. 1990) , which not only acts as a vasoconstrictor but also regulates smooth (Berk et al. 1989; Geisterfer et al. 1988 ) and cardiac muscle growth (Sadoshima et al. 1993; Ishigai et al. 1997 ). ACE inhibitors have been shown to inhibit hypertrophy in overloaded muscle, which also suggests a role for angiotensin II in skeletal muscle hypertrophy (Gordon et al. 2001; Westerkamp and Gordon 2005) .
α-Actinin-3 gene α-Actinin-3 (ACTN3) is a structural protein that is the predominant component of the sarcomeric Z-discs, where it acts as a lattice structure that anchors actinin-containing thin filaments and stabilises the muscle contractile apparatus (Squire 1997 ). This protein is almost exclusively expressed in fast-twitch (type II) skeletal muscle fibres (Mills et al. 2001) ; thus, compared to the I type, α-actinin-3 may confer type II fibres with a higher capacity for the absorption/transmission of force at the Z line during rapid contractions (Squire 1997) . The R577X polymorphism (rs1815739) of the gene (ACTN3) encoding α-actinin-3, which results from a C-to-T transition at position 1,747 in exon 16 that substitutes an arginine residue at codon 577 for a premature stop codon (North et al. 1999) , may be associated with muscle phenotypes, particularly with the ability to produce powerful muscle contractions (MacArthur et al. 2007 ). The α-actinin-3-deficient XX genotype (with a frequency of~18% among European Caucasians) is believed to preclude top-level athletic performance in 'pure' power and sprint sports (e.g. sprinting, jumping events), especially in women (Yang et al. 2003) . In contrast, compared with the general population, the X allele tends to be overrepresented in those humans with an 'extreme endurance phenotype', i.e. elite endurance athletes Yang et al. 2003) . Compared with the age-matched wild-type mouse, the ageing knockout (α-actinin-3-deficient) mouse shows greater loss of fast muscle force generation and male muscle mass, yet good maintenance of grip strength and increased oxidative metabolism and greater force recovery after fatigue (Seto et al. 2011 ).
Androgen receptor gene Androgen (total and free testosterone) concentrations decline progressively with advancing age because of defects at all levels of the hypothalamic-pituitary-testicular axis; low androgen levels have been associated with decreased skeletal muscle mass, muscle strength, physical function, bone mineral density, and fracture risk in older people (Bhasin and Storer 2009) . The androgen receptor (AR) gene contains a polymorphic trinucleotide CAG microsatellite repeat sequence in exon 1 that modifies either the amount of AR protein inside the cell (GGNn, polyglycine) or its transcriptional activity (CAGn, polyglutamine).
Ciliary neurotrophic factor gene The ciliary neurotrophic factor (CNTF) is a member of the interleukin-6 family that exerts trophic effects on both neuronal (Sleeman et al. 2000) and muscle tissues (Guillet et al. 1999) . Although CNTF synthesis is associated with peripheral nerves (Sendtner et al. 1992 ), a specific binding subunit of the CNTF receptor (CNTF receptor-α), abundantly expressed in skeletal muscle , is required for CNTF activity ). In addition, CNTF levels decline with age, and exogenous CNTF administration in older rats increases muscular strength (Guillet et al. 1999) . A G-to-A polymorphism (rs1800169) in the human CNTF gene that results in aberrant splicing was first identified by Takahashi et al. (1994) .
Collagen type I alpha 1 gene Type I collagen is the major protein of bone and is composed of two alpha1 and one alpha2 chains, which are encoded by collagen type I alpha 1 (COL1A1) and COL1A2 genes, respectively. Mutations in the coding regions of both genes give rise to different variants of osteogenesis imperfecta, an autosomal dominant disorder of the connective tissue that is characterized by a variable degree of bone fragility. Although Van Pottelbergh et al. (2001) found an association between a polymorphism in COL1A1 and muscle phenotypes (see "Cross-sectional genetic association studies" section below), the mechanisms explaining such association remain to be elucidated. Because both bone and muscle tissue deteriorate with age and bone geometry is partly determined by muscle mass/ strength, there might be a common genetic aetiology to sarcopenia and osteoporosis in the elderly, with some genetic variants contributing to both muscle and bone phenotypes (Karasik et al. 2009 ).
Follistatin and activin-type II receptor B genes Follistatin (FST) and activin-type II receptor B (ACVR2B) are two myostatin-related genes involved in the regulation and signalling of myostatin (see below for a detailed explanation on myostatin function).
Insulin-like growth factor genes Insulin-like growth factors (IGFs) are peptides that regulate the growth, differentiation and regeneration of cells (O'Dell and Day 1998). Insulin-like growth factor II (IGFII or IGF2) is one of the main determinants of foetal and post-natal growth (Rother and Accili 2000) . It has also a proliferative action in adult muscle (Caroni et al. 1994) , and the age-associated loss in muscle fibres may be related, at least partly, to a decline in the local production of IGFs like IGF2 (Sayer et al. 2002) .
Interleukin-6 gene Interleukin-6 (IL6) is a multifunctional cytokine primarily involved in immune functions. Recent data also indicate a pivotal role of this protein in the processes of muscle repair and hypertrophy following exercise-induced damage (Serrano et al. 2008) . A functional G/C polymorphism at position −174 [rs1800795] was described in the 5′ flanking region of the IL6 (IL6) gene (Fishman et al. 1998) , with the G allele being associated with increased transcriptional response in vitro (Fishman et al. 1998 ) and in vivo conditions (Bennermo et al. 2004 ).
Myostatin gene The myostatin (MSTN; or growth differentiation factor 8) gene (Huygens et al. 2004 ) is receiving growing attention in the last years. The MSTN gene encodes myostatin, a skeletal musclespecific secreted peptide that functions mainly to modulate myoblast proliferation and thus muscle mass and strength . Variants of the MSTN gene are associated with muscle hypertrophy phenotypes in a range of mammalian species, most notably cattle (Grobet et al. 1997; , dogs (Mosher et al. 2007 ) and mice . The myostatin-null mouse model also provides insights into the physiological role of this protein. Old myostatin-deficient mice have minimal muscle atrophy compared to their wild-type controls (Siriett et al. 2006 ). It appears that myostatin also regulates the structure and function of tendon tissues, as the stiffness of tendons is 14 times higher in myostatin-deficient mice than in their wild-type controls (Mendias et al. 2008) .
Myostatin inhibition, as well as variations in the MSTN gene, can have functional consequences in old humans. Systemic treatment with the myostatin inhibitor MYO-029 provides an adequate safety margin and can induce improvements in the muscle strength/function or muscle contractile properties of some adult patients with muscular dystrophies, supporting the bioactivity of myostatin inhibitors (Krivickas et al. 2009; Wagner et al. 2008) . Because this type of treatment could also stimulate muscle growth in healthy humans (Wagner et al. 2008) , it would be interesting to determine its effect in ageing people. Of the identified MSTN variations in humans, the Lys(K)153Arg(R) polymorphism located in exon 2 (rs1805086, 2,379A>G replacement) is one candidate to influence skeletal muscle phenotypes (Ferrell et al. 1999 ). The Lys(K)153Arg (R) amino acid replacement is found within the active mature peptide of the myostatin protein; it could theoretically influence proteolytic processing with its propeptide, or affinity to bind with the extracellular activin-type II receptor B. The latter results in intracellular activation of the SMAD pathway, through which myostatin induces myoblast proliferation (Thomas et al. 2000) and differentiation (Rios et al. 2002) , and thus muscle mass growth (Kostek et al. 2009 ). The frequency of the mutant R allele is~3-4% among Caucasians, with a frequency of mutant homozygotes (RR) below 1% (Corsi et al. 2002; Ferrell et al. 1999; Kostek et al. 2009 ). Such low allelic frequency obviously limits the possibility of studying large groups of people carrying the R variant.
Vitamin D receptor genotype Although there is some recent controversy with regards to its actual expression in skeletal muscle fibres (Wang and DeLuca 2011) , the vitamin D receptor (VDR) is thought to play an important role in calcium homeostasis and skeletal muscle function. Vitamin D deficiency can cause a myopathy of varying severity, and clinical studies have indicated that vitamin D status is positively associated with muscle strength and physical performance and inversely associated with risk of falling; in vitamin D-deficient older adults, vitamin D supplementation has been shown to improve tests of muscle function, reduce falls and possibly impact on muscle fibre composition and morphology (Ceglia 2008) . Molecular mechanisms of VDR action on muscle tissue include activation of signal transduction pathways in skeletal muscle cells through which vitamin D regulates contractility and myogenesis (Wang and DeLuca 2011) .
Cross-sectional genetic association studies
The information on cross-sectional studies is detailed in Table 1 . These studies reported the association of one or more polymorphisms with muscle phenotypes in old people at a single time point. Most studied subjects were sedentary. Some cross-sectional analyses were part of large studies including both cross-sectional and longitudinal designs, with the results of the latter being reported in the next section (see "Longitudinal genetic association studies").
The ACE I/D polymorphism is arguably the most widely studied genetic variation with regards to physical fitness phenotypes in humans, with controversial results (Bray et al. 2009 ). Published findings are also controversial in older people, starting with the possible association between this polymorphism and muscle mass. Some studies reported a positive association between the D allele and the following phenotypes: muscle mass in healthy inactive old men and women (Charbonneau et al. 2008) , lean mass (as well as handgrip force) in advanced cancer patients (Vigano et al. 2009 ) or appendicular fat free fat (FFM) in old women (Lima et al. 2011 ). In contrast, McCauley et al. found no association with whole body and thigh lean mass in old Caucasians (McCauley et al. 2010) .
Between-studies differences also exist for the potential association between ACE I/D genotypes and muscle strength and muscle fitness. Yoshihara and co-workers studied the relationship of the ACE I/ D variation with muscle and fitness phenotypes in old Japanese men and women who did not require special care for their daily activities (Yoshihara et al. 2009 ). They found the ACE I/D polymorphism to be associated with handgrip strength and 10-m maximum walking speed, but not with leg muscle extensor strength. We recently reported no association between ACE genotypes and handgrip strength, leg muscle strength and walking ability in Caucasian (Spanish) nonagenarians (Bustamante-Ara et al. 2010). Frederiksen et al. found no association between the ACE I/D polymorphism and baseline levels of muscle strength, walking speed or body composition in elderly Danes (Frederiksen et al. 2003a) . The same group found no association between ACE genotypes and the baseline levels of self-reported physical performance in a large cohort of old Danish twins (Frederiksen et al. 2003b) .
Published data on ACTN3 genotypes and specific muscle phenotypes in old people are also controversial. When present, the effect of ACTN3 genotypes in ageing muscle seems to be more marked in women. Our group found no association between ACTN3 genotype and functional capacity and muscle phenotypes (included leg muscle strength, sit-stand test and 1-mile walk test) in old Caucasian women (San Juan et al. 2006 ). This preliminary finding was overall corroborated in other studies. Delmonico et al. found no association of the ACTN3 R577X polymorphism with muscle strength (knee extensor) and physical performance (short physical performance battery score, and 400-m walk time) in a large cohort of old men and women . McCauley et al. reported no association between this polymorphism and knee extension muscle strength or indices of muscularity (whole body or thigh nonskeletal lean mass) in old Caucasian men (McCauley et al. 2010) . Recently, we observed no major influence of ACTN3 genotypes on muscle phenotypes (leg and grip strength, walking and stair climbing ability) in nonagenarians (mostly women) (Bustamante-Ara et al. 2010). Lima et al. found no effect of the ACTN3 R577X variation in quadriceps VDR BsmI (rs1544410), VDR FokI (rs2228570) Both patients and control subjects who were homozygous for the C allele of the FokI polymorphism had less quadriceps strength than did those with ≥1 T allele (P≤0.01).
The BsmI b allele was associated with greater quadriceps strength in patients but had no effect in healthy control subjects. strength (using isokinetics) at baseline in Brazilian old women (Lima et al. 2011) . In contrast, others found an association between the ACTN3 R577X variation and muscle phenotypes in old people, yet with controversial results with regards to which allele (R or X) has a favourable or unfavourable effect. Delmonico and co-workers found that the XX genotype was associated with higher knee extensor concentric peak power compared with RR/ RX genotypes, especially in old women (Delmonico et al. 2007 ), whereas in old women from another cohort the XX genotype was associated with lower peak torque in knee extensor muscles (Walsh et al. 2008) . In women, the XX genotype was associated with a greater risk of incident lower extremity limitation compared to RR.
Findings on ACTN3 genotypes and muscle mass are also controversial. Delmonico et al. found no association between the ACTN3 R577X polymorphism and mid-thigh CSA in older men and women . McCauley et al. found no association with indices of muscularity (whole body or thigh non-skeletal lean mass) in older Caucasian men (McCauley et al. 2010) . In contrast, in the aforementioned study by Lima et al. women who were X allele carriers presented higher relative FFM at baseline compared with RR women (Lima et al. 2011) . Zempo et al. (2010) showed that Japanese women with the XX genotype had lower thigh muscle CSA compared with RR and RX genotypes. Finally, in a recent study by Judson et al., carriage of the X allele (one or two copies) was significantly associated with increased risk of falling (Judson et al. 2011) .
The AR CAG repeat polymorphism was associated with (FFM) in men of two independent North American cohorts, with men bearing greater CAG repeat number exhibiting significantly higher total FFM than those with fewer CAG repeats (Walsh et al. 2005) . However, other studies reported no association of CAG repeat length with body composition (Lapauw et al. 2007) or with physical performance in old men (Kenny et al. 2005) .
Roth et al. found an association between the A null allele of the CNTF rs1800169 and quadriceps muscle strength in a large cohort of individuals with a wide age range, with higher values in GA individuals compared with the wild-type (GG) genotype (Roth et al. 2001 ). This genotype effect was more profound in people over 60 years. Arking et al. (2006) studied eight polymorphisms at the CNTF locus, including the G-to-A polymorphism (rs1800169) variation, in old Caucasian women. The authors performed haplotype analysis, with the rs1800169 null allele fully explaining haplotype association with handgrip strength under a recessive model; AA individuals exhibited significantly lower handgrip strength. A comparable (not significant) trend was observed for hip flexion and knee extension strength (both assessed with a handheld isometric dynamometer). There was, however, no significant association between the CNTF null allele and frailty syndrome.
A study designed to examine the association of the COL1A1 Sp1 binding site polymorphism (rs1800012) with indices of muscle strength found that mean handgrip and biceps strength were lower in the unfavourable ss group compared with the SS group, whereas no differences were noted for lower limb strength (Van Pottelbergh et al. 2001 ). Walsh et al. studied the associations of both FST and ACVR2B with skeletal muscle-related phenotypes in men and women ). FST and ACVR2B were genotyped to determine respective haplotype groupings based on HapMap data. Women carriers of ACVR2B haplogroup 1 exhibited significantly less quadriceps muscle strength than women homozygous for haplogroup 2, while men carriers of FST haplogroup 3 exhibited significantly less total leg FFM than non-carriers. The authors concluded that ACVR2B and FST haplogroups may contribute to inter-individual variation in skeletal muscle mass and strength, although genotype-phenotype associations seem to be sex specific.
Sayer et al. studied old men and women who had historical records of birth weight to determine whether the IGF2 820G>A (ApaI, rs680) polymorphism explains the link between size at birth and grip strength in later life (Sayer et al. 2002) . Their results indicated that IGF2 ApaI genotype and birth weight were independent predictors of grip strength in men with both variables exerting additive effects, but not in women. Schrager et al. reported that IGF2 ApaI genotypes influenced muscle mass and function at age 65 years, with the AA genotype exerting a negative effect on the isokinetic arm strength of men and on the total body FFM and isokinetic arm and leg strength of women (Schrager et al. 2004) ; however, these results were only corroborated in one of two studied North American cohorts. On the other hand, although elevated levels of IL6 can be associated with the development of disability, frailty and mortality in older adults, Walston et al. found no significant relationship between IL6 174 G/C genotypes and serum IL6 levels, grip, knee or hip strength, or frailty in old women (Walston et al. 2005) .
Despite controversy existing with regards to adults (Kostek et al. 2009 ), the MSTN K153R polymorphism is likely associated with muscle phenotypes in old people, with the infrequent mutant R allele possibly exerting a negative influence (Ferrell et al. 1999; Huygens et al. 2004; Seibert et al. 2001) . In a cohort of old African-American women, Seibert et al. reported lower muscle strength in those who carried the variant 153R allele (Seibert et al. 2001) . Similar findings were reported by Corsi et al. for the isometric strength assessed in eight muscle groups in Italian Caucasians (Corsi et al. 2002) . We recently reported that the muscle mass and function (especially gait and balance ability, as assessed with the Tinetti scale, and capacity for performing daily life activities independently, as assessed with the Barthel score) of a very old woman (age 96 years) with the very rare MSTN 153RR genotype was in the lowest 25th sex-and agespecific percentile (Gonzalez-Freire et al. 2010 ). In the same study, the muscle strength and mass of KR women were low to normal (~25th-50th percentile) compared to the wild-type (KK) genotype, yet their functional capacity (Barthel and Tinetti tests) was normal. Corsi et al. also found a Caucasian person (assumed age <80 years) with the rare RR genotype, yet with no specification on individual phenotype data (Corsi et al. 2002) .
Some studies showed a beneficial effect of the b allele of the VDR BsmI polymorphism (rs1544410) in the muscle function of older people. Two studies found an association between VDR BsmI genotypes and muscle strength in postmenopausal women (Vandevyver et al. 1999 ) and in healthy (non-obese) old women (Geusens et al. 1997) , with bb individuals exhibiting significantly higher quadriceps strength than those with the BB genotype, yet this association was not corroborated in obese old women (Geusens et al. 1997) . Hopkinson et al. (2008) reported that the b allele of the BsmI polymorphism was associated with greater quadriceps strength in patients with chronic obstructive disease, but had no effect in healthy controls. Both patients and controls that were homozygous for the C allele of the VDR FokI polymorphism (rs2228570) had less quadriceps strength than those with one or more T alleles. In a study of Italian nonagenarians (men and women), the BsmI bb genotype was associated with a reduced rate of falls compared with the BB genotype, whereas no effect was shown for the FokI polymorphism (Onder et al. 2008 ). Barr et al. analysed five polymorphisms of the VDR gene [Cdx2 (rs11568820), FokI, BsmI, TaqI (rs731236) and Apa1 (rs7975232)] in postmenopausal women and showed that carriers of the BsmI B allele had an increased risk for falls (Barr et al. 2010 ). The BsmI polymorphism was also associated with balance and muscle power. In contrast, Bahat et al. (2010) reported a beneficial effect associated with the BsmI B allele, with BB homozygotic old men showing higher knee extensor muscle strength compared with the Bb/bb group. However, no association existed between BsmI genotypes and muscle mass, and VDR TaqI and FokI polymorphisms were not associated with muscle phenotypes.
There is also controversy with regards to the potential association between VDR genotypes and muscle mass in the elderly. Moreno Lima et al. (2007) found no genotype association between VDR polymorphisms (ApaI, Cdx2, BsmI, FokI and TaqI) and FFM in old Brazilian women. Similar findings were obtained by Bahat et al. (2010) , who showed no effect of BsmI, TaqI and FokI genotypes on the muscular mass of old men. In contrast, Roth et al. (2004) found higher risk for sarcopenia in FF homozygotes for the FokI polymorphism compared to men with one or more f alleles. No significant effect was, however, noted for the BsmI polymorphism.
Longitudinal genetic association studies
The information on longitudinal studies is detailed in Table 2 . These studies reported phenotype assessment at two or more time points. Many, but not all, of these studies assessed the effects of an exercise training intervention. Frederiksen et al. (2003a) found no association between the ACE I/D polymorphism and time changes (whether induced by training or not) of muscle strength, walking speed or body composition in elderly Danes. In a 2-year longitudinal study on a large cohort of twins, the same group found no association between ACE genotypes and the time changes in self-reported physical performance (Frederiksen et al. 2003b) . Individual physical activity levels might influence the possible interaction between the ACE I/D polymorphism and muscle phenotypes. Kritchevsky et al. (2005) studied the interaction between ACE I/D genotype, high levels of physical activity and functional decline over time (mean follow-up of~4 years) in a large cohort of well-functioning community-dwelling old men. Physically active participants (i.e. those reporting expending ≥1,000 kcal week −1 in exercise, walking and stair climbing) were less likely to develop mobility limitation regardless of genotype, but physical activity levels interacted significantly with the ACE genotype. In the inactive group, the ACE genotype was not associated with mobility limitation, whereas among active subjects, those who had the II genotype were more likely to develop mobility limitation compared with the rest of genotypes. Some studies have analysed the association between the ACE I/D variation and muscle responsiveness to specific exercise training programmes. Charbonneau et al. (2008) found no association between the ACE I/D polymorphism and the muscle volume adaptation to resistance training (RT). In contrast, in a study with obese old people, Giaccaglia et al. (2008) found greater gains in knee extensor strength in DD homozygotes compared with II homozygotes after 18 months of walking and light RT. However, no genotype association was found with the muscle volume adaptation in response to RT. Lima et al. (2011) recently reported that, among old Brazilian women who performed quadriceps RT during 24 weeks, FFM was increased after training only in the I allele carriers.
There are controversies and sex differences with regards to the putative effects over time of ACTN3 R577X genotypes on muscle phenotypes. In a 5-year follow-up study, Delmonico et al. (2008) found that XX men had higher increase in 400-m walk time compared with RR or RX men. In contrast, XX women had a greater risk of incident persistent lower extremity limitation compared to RR women. The same group examined knee extensor concentric peak power after~10 weeks of unilateral knee extensor RT in older men and women (Delmonico et al. 2007 ). In men, absolutes changes in peak power after training approached a significantly higher value in the XX group, whereas women with the RR genotype showed significantly greater training improvements in relative peak power than their XX counterparts. However, Lima et al. (2011) reported no significant association between ACTN3 genotypes and RT adaptations. Finally, a recent report showed that carriage of the X allele (one or two copies) was significantly associated with increased risk of falling over time (Judson et al. 2011) . Schrager et al. (2004) studied the influence of IGF2 ApaI genotypes on total body FFM, muscle strength and sustained power repeatedly at ∼2-year intervals in two North American cohorts of men and women of different ethnic origin (Caucasian and African-American, respectively). The results did not support the hypothesis that A/A individuals have greater rates of age-associated decline in muscle phenotypes than G/G individuals. In fact, G/G men demonstrated an unexpected greater rate of loss in FFM compared with A/A men. No significant genotype effect was noted in women.
Some preliminary findings might suggest a possible role for the MSTN K153R polymorphism in the muscle volume response to RT, yet definitive data in old people are missing. Ivey et al. (2000) found a trend towards a genotype effect on the muscle volume response to RT, such that women of varying ages (23-73 years) with the KR genotype exhibited a higher increase in trained leg muscle volume after 9 weeks of RT than their age and sex-matched peers with the KK genotype.
Research gaps in the field and recommendations
Between-studies differences in several methodological aspects might explain, at least partly, the controversy existing in the field. Besides disparities in the choice of candidate polymorphisms, there are also differences among studies in age of the participants and in the tests for muscle mass and muscle strength/function assessment. For instance, 1-repetition maximum (1RM) strength tests or the 1-mile walk test are often used in healthy sexagenarians or septuagenarians, whereas more debilitated or older cohorts (typically, nonagenarians) are better assessed with tests of ambulation ability. Thus, although a meta-analysis would have provided a more accurate perspective that the type of review we performed here, we believe such type of systematic review cannot be performed at present due to heterogeneity among studies. There is a clear need to improve as much as possible the methodology of research examining the association between specific genetic variants and muscle phenotypes in old people. Future studies should adhere to the recent guidelines for 'Strengthening the Reporting of Genetic Association' (STREGA) studies (Little et al. 2009 ). The STREGA Statement was built on the 'Strengthening the Reporting of Observational Studies in Epidemiology' (STROBE) Statement and provides additions to 12 of the 22 items on the STROBE checklist. The additions concern population stratification, genotyping errors, modelling haplotype variation, Hardy-Weinberg equilibrium, replication, selection of participants, rationale for choice of genes and variants, treatment effects in studying quantitative traits, statistical methods, relatedness, reporting of descriptive and outcome data and the volume of data issues that are important to consider in genetic association studies. Many genetic association studies performed in the last decade did obviously not adhere to STREGA guidelines and thus are difficult to compare with future studies that might follow these guidelines.
On the other hand, the current knowledge on genetic factors associated with human muscle phenotypes comes mainly from Caucasian cohorts. It is necessary to replicate previously reported associations between genetic polymorphisms and muscle phenotypes in other cohorts of different ethnic origin. An additional potential gap to be kept in mind when interpreting the literature in the field is that studies reporting no genetic association (i.e. 'negative results') are less 'attractive' and thus less likely to be published than others showing 'statistical significance' ('positive results').
Most reports in the field have used a candidate gene approach based on the rationale that a single gene (or a few genes) plays an important function in muscle phenotypes (e.g. ACTN3 is crucial for muscles' ability to produce 'power'). However, the more 'agnostic approach' provided by 'genome-wide association' (GWA) studies may also add valuable information. This type of studies evaluates the association of genetic variation with outcomes or traits of interest by using 100,000 to 1 million or more markers across the genome without any previous hypotheses about potential mechanisms (Attia et al. 2009 ). In a recent GWA study, Liu et al. tested 379,319 single nucleotide polymorphisms (SNPs) in a cohort of US unrelated whites (n=492 men and 481 women) with a mean age of 50 years (Liu et al. 2009 ). They found that two SNPs, rs16892496 and rs7832552 within the thyrotropin-releasing hormone receptor (TRHR) gene were significantly associated with LBM. Subjects carrying unfavourable genotypes at rs16892496 and rs7832552 had, on average, 2.70 and 2.55 kg lower LBM, respectively, compared to those with alternative genotypes. The results were replicated in (a) another cohort of unrelated US whites (659 men, 829 women, mean age of 63 and 61 years, respectively), (b) Chinese unrelated subjects (1,437 men, 1,518 women, mean age of 30 and 35 years) and (c) 593 nuclear families comprising 1,972 US whites (mean age of men and women of 53 and 47 years, respectively). Thus, their findings support the TRHR gene as an important gene for LBM variation. GWA studies and simpler genotypephenotype association studies focusing on just one or few polymorphisms (as the ones we extensively reviewed in this paper) are not mutually exclusive. More GWA as the one by Liu et al. (2009) are needed in older people (a) to interrogate traditional candidates that are thought to play an influence on muscle phenotypes and (b) to propose new candidate genes. The latter inevitably implies replication and more detailed analyses in genotype-phenotype association studies, e.g. recent findings on the TRHR gene should be replicated in association studies focusing on this gene and its putative influence on the baseline and training response of well-defined muscle phenotypes in old people.
Studies investigating gene expression analysis are also recommended, in order to better understand the molecular mechanisms underlying the potential association between a given polymorphism and muscle phenotypes at advanced age. Nonetheless, ideally this would require collecting skeletal muscle biopsies, which might not be easily feasible in the elderly. The relevant information that can be obtained with gene expression studies is best exemplified by a recent study on the RNA expression of 17,881 genes at the skeletal muscle level in a cohort of healthy Pima Indians (age range 18-50 years) (Mason et al. 2011) . Using exon array expression chips, the authors found ACTN3 to be one of the only eight genes that showed bimodal expression. Both modes were at levels indicative of transcript abundance, with the distinct separation in expression levels being nearly completely explained by rs509556, which is in perfect linkage disequilibrium with the ACTN3 R577X polymorphism. Thus, future expression studies in the elderly might also help providing new insights into the genetic associations of important disease phenotypes in this population. For instance, the authors of the aforementioned study found that insulin sensitivity was higher in those individuals with the low mode of ACTN3 expression (Mason et al. 2011) .
Conclusions
In summary, although previous heritability studies have indicated that there is an important genetic contribution to the individual variability in muscle phenotypes among old people published data on specific gene variants are controversial. To date, no solid evidence exists supporting the existing of an 'unfavourable' genotype, e.g. associated with accelerated sarcopenia or loss of independence. Although the ACTN3 R577X polymorphism is the only structural gene for which a clear genotype effect has been shown in human muscle phenotypes, especially for athletic women, there is controversy with regards to which allele (R or X) plays a potential 'favourable' role in old people. The MSTN K153R variation is possibly the strongest candidate to explain variance among muscle phenotypes in the elderly, yet more research is still needed with large cohorts owing to the very low population frequency of the 'unfavourable' 153R allele.
Age declines in muscle phenotypes are likely polygenic traits and thus not reducible to specific polymorphisms. Future studies should take into account the association between muscle phenotypes in older people and (a) complex gene-gene interactions, including those interactions between genetic variants that might not influence muscle phenotypes individually, and (b) the interaction between genes and environmental/external factors, particularly physical activity.
